GlassScriptPhysician profile
Claire Trappey
NPI 1275685968
$4,033.33
in general payments reported to CMS, 2019-2025
42 companies · $956 in 2025
The $956 reported for 2025 was more than what 84% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,022 · 2022: $761 · 2023: $526 · 2024: $768 · 2025: $956.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,249.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $492.18 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $467.54 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $447.14 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $333.63 | 2023-2025 | |
| Abbvie INC. | $312.69 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $248.64 | 2021-2025 | Xifaxan, Trulance |
| Astellas Pharma US INC | $179.37 | 2021-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $167.63 | 2021-2024 | Synjardy, Jardiance, Tradjenta |
| Biohaven Pharmaceutical Holding Company LTD. | $137.55 | 2022 | |
| Paratek Pharmaceuticals, INC. | $92.16 | 2021-2022 | |
| Abiomed | $72.97 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $72.82 | 2022-2024 | Rexulti |
| Inspire Medical Systems, INC. | $68.85 | 2025 | Inspire |
| Antares Pharma, INC. | $67.15 | 2024-2025 | Xyosted |
| Phathom Pharmaceuticals, INC. | $58.93 | 2024-2025 | Voquezna |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Claire Trappey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.